WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005112635) URIDINE EFFECTS ON DOPAMINE RELEASE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/112635    International Application No.:    PCT/US2005/016452
Publication Date: 01.12.2005 International Filing Date: 11.05.2005
IPC:
A01N 43/04 (2006.01), A01N 57/26 (2006.01), A61K 31/70 (2006.01), A61K 31/685 (2006.01)
Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US) (For All Designated States Except US).
WURTMAN, Richard, J. [US/US]; (US) (For US Only)
Inventors: WURTMAN, Richard, J.; (US)
Agent: COHEN, Mark, S.; Pearl Cohen Zedek Latzer LLP, 10 Rockefeller Plaza, Suite 1001, New York, NY 10020 (US)
Priority Data:
60/570,444 13.05.2004 US
Title (EN) URIDINE EFFECTS ON DOPAMINE RELEASE
(FR) EFFETS DE L'URIDINE SUR LA LIBERATION DE LA DOPAMINE
Abstract: front page image
(EN)The present invention provides methods for increasing secretion of dopamine and other neurotransmitters and treating or reducing the incidence of diseases involving decreased secretion of dopamine and other neurotransmitters, e.g. Parkinson's disease, comprising administering to the subject a uridine or a source thereof, and compositions for treating or reducing an incidence of Parkinson's disease, comprising a uridine, a uridine monophosphate, or a source thereof.
(FR)L'invention concerne des procédés permettant d'augmenter la sécrétion de la dopamine et d'autres neurotransmetteurs et de traiter ou réduire l'incidence de maladies impliquant une baisse de la sécrétion de la dopamine et d'autres neurotransmetteurs, par exemple la maladie de Parkinson, qui consistent à administrer au patient une uridine ou une source de celle-ci, ainsi que des compositions permettant de traiter ou de réduire l'incidence de la maladie de Parkinson, qui renferment une uridine, un monophosphate d'uridine, ou une source de ceux-ci.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)